Sipagladenant | 858979-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Sipagladenant
• 英文别名: N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide
• CAS: 858979-50-7
• 化学式: C₂₀H₁₉N₃O₄S
• 分子量: 397.4
• InChiKey: KMFLQPJJHQNKKF-UHFFFAOYSA-N

物化性质

• 密度：
  1.353±0.06 g/cm3(Predicted)
• pKa：
  5.31±0.70 (Predicted,Most Acidic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [4-(2-Furanyl)-2-[(1-methyl-1-phenylethyl)amino]-5-thiazolyl](tetrahydro-2H-pyran-4-yl)methanone 在 三氟乙酸 、 碳酸氢钠 、 N,N'-羰基二咪唑 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以84 %的产率得到Sipagladenant
  参考文献：
  名称：

  [EN] PRODUCTION METHOD OF THIAZOLE DERIVATIVE
  [FR] PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ THIAZOLE

  摘要：

  Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).

  公开号：

  WO2016111381A1

文献信息

• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。
• THERAPEUTIC AGENT FOR MIGRAINE
  申请人：Ikeda Junichi

  公开号：US20110183992A1

  公开（公告）日：2011-07-28

  Provided are therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A 2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof; therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A 2A receptor antagonistic activity, which has an affinity for the adenosine A 2A receptor 10 times or higher than that for the adenosine A 1 receptor, or a pharmaceutically acceptable salt thereof; and the like.

  提供了治疗和/或预防偏头痛的药物，其作为活性成分包含具有选择性腺苷A2A受体拮抗活性的化合物或其药学上可接受的盐；作为活性成分包含具有选择性腺苷A2A受体拮抗活性的化合物的治疗和/或预防偏头痛药物，其与腺苷A1受体相比具有10倍或更高的亲和力，或其药学上可接受的盐；等等。
• THIAZOLE DERIVATIVES
  申请人：Nakajima Takao

  公开号：US20110105486A1

  公开（公告）日：2011-05-05

  Wherein n is an integer of from 0 to 3; R 1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R 2A is —COR 8 (wherein R 8 is aryl); R 3A is hydrogen or lower alkyl; and R 12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R 1A , R 2A , R 3A and R 12 are individually optionally substituted.

  其中n是0到3的整数；R1A是一个含有至少一个氧原子的5-成员芳香杂环基团；R2A是-COR8（其中R8是芳香基）；R3A是氢或较低的烷基；而R12代表环烷基，芳香基，芳基烷基，脂环杂环基团，芳香杂环基团，脂环杂环烷基或芳香杂环烷基，R1A，R2A，R3A和R12都可以个别地选择性地被取代。
• THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER
  申请人：Uesaka Noriaki

  公开号：US20100152162A1

  公开（公告）日：2010-06-17

  It is intended to provide an agent for treating and/or preventing sleep disorder containing as an active ingredient a thiazole derivative represented by the general formula (I) (in the formula, R 1 represents a five-membered aromatic heterocyclic group containing at least one oxygen atom or the like, R 2 represents halogen or the like, and R 3 represents —NR 10 R 11 (in the formula, R 10 and R 11 are the same or different and represent a hydrogen atom or the like) or the like) or a pharmacologically acceptable salt thereof.

  该发明旨在提供一种治疗和/或预防睡眠障碍的药剂，其活性成分为一种由通式（I）表示的噻唑衍生物（在公式中，R1表示至少含有一个氧原子的五元芳香杂环基团或类似基团，R2表示卤素或类似基团，R3表示-NR10R11（在公式中，R10和R11相同或不同，表示氢原子或类似基团）或类似基团）或其药理学上可接受的盐。
• Therapeutic agent for motor disorders
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US10407440B2

  公开（公告）日：2019-09-10

  Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R1 represents aryl and the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

  提供了一种用于治疗和/或预防运动障碍的制剂，该制剂用于治疗和/或预防运动障碍，其中运动障碍是锥体外系综合征，该制剂用于治疗和/或预防运动障碍，其中运动障碍是运动迟缓、步态障碍、肌张力障碍、运动障碍或迟发性运动障碍、治疗和/或预防运动障碍的药物，其中运动障碍是 L-DOPA 和/或多巴胺受体激动剂治疗的副作用等，每种药物都含有式（I）代表的噻唑衍生物，其中 R1 代表芳基等，R2 代表吡啶基等，或其药学上可接受的盐作为活性成分。